News Daily News Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca Caitlin E. Cox October 04, 2016
News Conference News PCR London Valves 2016 Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance Shelley Wood September 22, 2016
News Conference News PCR London Valves 2016 TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients Shelley Wood September 20, 2016
News Daily News Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe Michael O'Riordan September 20, 2016
News Conference News PCR London Valves 2016 Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon Shelley Wood September 20, 2016
News Conference News PCR London Valves 2016 Innovation Overload? Too Many Novel Ideas May Be Holding Back Progress in Transcatheter Mitral Valve Technologies Shelley Wood September 19, 2016
News Industry News Edwards Sapien 3 Transcatheter Heart Valve Receives Expanded Indication In Europe September 19, 2016
News Daily News Elderly Asymptomatic Patients With Severe AS Are Often Treated Too Late L.A. McKeown September 16, 2016
News Daily News La Endocarditis Infecciosa Post-TAVR se asocia a Diabetes, Regurgitación Aórtica Residual en un Extenso Registro Yael L. Maxwell September 14, 2016
News Daily News Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns Shelley Wood September 13, 2016
News Daily News Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas Shelley Wood September 13, 2016
News Conference News ESC 2016 Valve Thrombosis After TAVR Linked to Larger Device Size, Lack of Warfarin Therapy Todd Neale September 02, 2016
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for August 2016 Caitlin E. Cox September 01, 2016
News Conference News ESC 2016 New Cardio-Oncology Position Statement Reviews Cardiovascular Side Effects of Cancer Therapies and Calls for Further Study Shelley Wood August 27, 2016
News Daily News TAVR as an Option for Intermediate-Risk Patients: Physicians Respond Yael L. Maxwell August 24, 2016
News Daily News Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients L.A. McKeown August 24, 2016
News Daily News Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo L.A. McKeown August 24, 2016